private medical care
- rondo Daszyńskiego 1, Wola, WarszawaWarszawa, Masovian
- offer expired 25 days ago
- contract of employment
- specialist (Mid / Regular)
- hybrid work
As part of the company’s unprecedented growth and expansion, Moderna is taking an important step in the evolution of the organization in building a world-class, international Global Business Services (GBS) center based in Warsaw, Poland. The Global Business Services center will house talent in Finance, Pharmacovigilance, HR, Digital, Compliance among many other functions as it builds a foundation for shared services, internationally.
A key goal for the Chief Accountant will be to ensure the highest level of service in the completion of month-end close related tasks and the preparation of statutory financial statements for the legal entities in her/his remit. The successful candidate will contribute to continuous improvements in our financial close and reporting processes and related SOX internal controls. This position will also play an important part in collaborating with stakeholders across the Company on our financial policies and processes. This role will partner with the US Accounting team, the Director International Accounting, and other functional teams to drive an accurate and complete close process, and to identify and provide solutions for process enhancements.
Here’s What You’ll Do:
• Serve as a key contributor in the monthly and quarterly close and financial reporting process for the relevant legal entities
• Prepare monthly journal entries, account reconciliations and variance analysis while ensuring accuracy and adherence to US GAAP and local statutory requirements
• Actively contribute to close process improvements to meet SEC filing timelines
• Support department goals, including implementations of accounting-related systems/applications and process improvements
• Support the external financial audits and the SOX 404 audits
• Ensure close controls are properly performed and adequately supported with workpaper documentation as required under SOX
• Establish and maintain strong business partnerships with key counterparts in our US and non-US based Finance Teams
Bachelor's degree in Accounting required
CPA and Big 4 public accounting firm experience preferred
4+ years of public accounting or combined public accounting and industry experience; biotechnology/pharmaceutical Industry experience is a plus
Strong knowledge of US GAAP, internal controls and supporting a timely close and reporting process
Experience with preparation of local statutory financial statements in various EU and APAC countries
Knowledge of life science, as well as commercial and manufacturing accounting transactions
Possess strong SOX internal controls background
Experience with financial systems including SAP, Blackline and Microsoft Suite of products
Strong work ethic, self-motivated, willing to “Roll-up your sleeves” to drive and deliver results, meet deadlines and improve processes
Strong analytical skills and pays attention to detail
Strong organizational, interpersonal, verbal and written communication skills
Ability to work collaboratively across functional teams
A desire to be part of a high-growth, transformational company that is Bold, Relentless, Curious, and Collaborative
employee referral program
generous computer glasses and contact lens reimbursement
1 month paid sabbatical after 5 years
Why we come to work every day?
Deliver on the promise of MRNA science to create a new generation of transformative medicines for patients.
The brand new Moderna International Business Center is an exciting next step in our global expansion. Based in the heart of Warsaw, it provides our growing organization with innovative and strategic support to help scale our business for the benefit of people and patients around the world.
We offer an opportunities in Digital, Finance, Human Resources, Pharmacovigilance and Supply Chain.
Welcome to Moderna. We believe mRNA is the “software of life."
Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease.
Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients.
We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured.
Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform, the infrastructure to accelerate drug discovery and early development, a rapidly expanding pipeline, and a world-class team. Our pipeline includes development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas, and we have multiple clinical trials underway with other development candidates progressing toward the clinic. In addition, we have numerous discovery programs advancing toward development.